Surrozen, Inc./DE (SRZN) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $385.95M; Retained Earnings (Accumulated Deficit)USD $-604.61M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $376.64M; Retained Earnings (Accumulated Deficit)USD $-654.79M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $339.52M; Retained Earnings (Accumulated Deficit)USD $-527.28M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $1.00K; Additional Paid in CapitalUSD $320.61M; Retained Earnings (Accumulated Deficit)USD $-344.13M.
Surrozen, Inc./DE Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD |
|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $1.00K | $385.95M | $-604.61M | $-218.66M | (m) |
| 2026-03-31 | $0.00 | $1.00K | $376.64M | $-654.79M | $-278.15M | (m) |
| 2025-12-31 | $0.00 | $1.00K | $339.52M | $-527.28M | $-187.76M | (m) |
| 2025-09-30 | $0.00 | $1.00K | $320.61M | $-344.13M | $-23.52M | (m) |
| 2025-06-30 | $0.00 | $1.00K | $319.60M | $-272.48M | $47.11M | (m) |
| 2025-03-31 | $0.00 | $1.00K | $317.90M | $-312.23M | $5.67M | (m) |
| 2024-12-31 | $0.00 | $0.00 | $263.88M | $-285.26M | $-21.38M | (m) |
| 2024-09-30 | $0.00 | $0.00 | $262.89M | $-257.22M | $5.67M | (m) |
| 2024-06-30 | $0.00 | $0.00 | $261.85M | $-255.79M | $6.06M | (m) |
| 2024-03-31 | $0.00 | $0.00 | $260.66M | $-230.53M | $30.14M | (m) |
| 2023-12-31 | $0.00 | $0.00 | $259.63M | $-221.69M | $37.94M | $0.00 |
| 2023-09-30 | $0.00 | $3.00K | $258.31M | $-212.78M | $45.53M | $1.00K |
| 2023-06-30 | $0.00 | $3.00K | $257.39M | $-202.34M | $55.06M | $5.00K |
| 2023-03-31 | $0.00 | $3.00K | $256.03M | $-192.95M | $63.04M | $-50.00K |
| 2022-12-31 | $0.00 | $0.00 | $254.90M | $-178.65M | $76.00M | $-241.00K |
| 2022-09-30 | $0.00 | $4.00K | $255.79M | $-177.88M | $77.49M | $-424.00K |
| 2022-06-30 | $0.00 | $4.00K | $254.69M | $-164.52M | $89.70M | $-476.00K |
| 2022-03-31 | $0.00 | $4.00K | $253.68M | $-150.60M | $102.66M | $-429.00K |
| 2021-12-31 | $0.00 | $4.00K | $252.46M | $-142.65M | $109.70M | $-119.00K |
| 2021-09-30 | (m) | $4.00K | $251.44M | $-127.69M | $123.73M | $-16.00K |
| 2021-06-30 | (m) | (m) | $10.94M | $-5.94M | $22.82M | (m) |
| 2021-03-31 | (m) | (m) | $7.35M | $-2.36M | $34.85M | (m) |
| 2020-12-31 | $0.00 | $2.00K | $135.29M | $-88.00M | $47.29M | $0.00 |
| 2020-09-30 | (m) | (m) | $24.77K | $-4.96K | $57.91M | (m) |
| 2020-08-20 | (m) | (m) | (m) | (m) | $0.00 | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | $66.38M | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | $23.30M | (m) |
| 2019-12-31 | (m) | (m) | (m) | (m) | $29.39M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |